137 related articles for article (PubMed ID: 10065898)
21. Effect of nitric oxide-releasing aspirin derivative on gastric functional and ulcerogenic responses in rats: comparison with plain aspirin.
Takeuchi K; Ukawa H; Konaka A; Kitamura M; Sugawa Y
J Pharmacol Exp Ther; 1998 Jul; 286(1):115-21. PubMed ID: 9655849
[TBL] [Abstract][Full Text] [Related]
22. Rx for stroke: aspirin, within 48 hours.
Heart Advis; 2002 Sep; 5(9):2. PubMed ID: 12243142
[No Abstract] [Full Text] [Related]
23. Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats.
Tashima K; Fujita A; Umeda M; Takeuchi K
Life Sci; 2000 Aug; 67(13):1639-52. PubMed ID: 10983857
[TBL] [Abstract][Full Text] [Related]
24. Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans.
Fiorucci S; Mencarelli A; Meneguzzi A; Lechi A; Renga B; del Soldato P; Morelli A; Minuz P
J Am Coll Cardiol; 2004 Aug; 44(3):635-41. PubMed ID: 15358033
[TBL] [Abstract][Full Text] [Related]
25. NCX4016: a novel antithrombotic agent.
Gresele P; Momi S; Mezzasoma AM
Dig Liver Dis; 2003 May; 35 Suppl 2():S20-6. PubMed ID: 12846440
[TBL] [Abstract][Full Text] [Related]
26. New nitric oxide or hydrogen sulfide releasing aspirins.
Lazzarato L; Chegaev K; Marini E; Rolando B; Borretto E; Guglielmo S; Joseph S; Di Stilo A; Fruttero R; Gasco A
J Med Chem; 2011 Aug; 54(15):5478-84. PubMed ID: 21688846
[TBL] [Abstract][Full Text] [Related]
27. NCX-4016 NicOx.
Di Napoli M; Papa F
Curr Opin Investig Drugs; 2003 Sep; 4(9):1126-39. PubMed ID: 14582459
[TBL] [Abstract][Full Text] [Related]
28. Myocardial protection by the nitroderivative of aspirin, NCX 4016: in vitro and in vivo experiments in the rabbit.
Rossoni G; Berti M; Colonna VD; Bernareggi M; Del Soldato P; Berti F
Ital Heart J; 2000 Feb; 1(2):146-55. PubMed ID: 10730616
[TBL] [Abstract][Full Text] [Related]
29. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016).
Corazzi T; Leone M; Maucci R; Corazzi L; Gresele P
J Pharmacol Exp Ther; 2005 Dec; 315(3):1331-7. PubMed ID: 16144976
[TBL] [Abstract][Full Text] [Related]
30. Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses.
Takeuchi K; Suzuki K; Yamamoto H; Araki H; Mizoguchi H; Ukawa H
J Physiol Pharmacol; 1998 Dec; 49(4):501-13. PubMed ID: 10069692
[TBL] [Abstract][Full Text] [Related]
31. Aspirin may cut heart disease deaths in women with heart disease.
Cardiovasc J S Afr; 2006; 17(1):37. PubMed ID: 16547561
[No Abstract] [Full Text] [Related]
32. Triple Antithrombotic Therapy - Always One Too Many?
Fukaya H; Ako J
Circ J; 2016; 80(2):316-7. PubMed ID: 26763466
[No Abstract] [Full Text] [Related]
33. Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG.
Lorusso R; De Cicco G; Beghi C; Gherli T; Poli E; Corradi D; Maestri R; Bonadonna S; Mancini T; Giustina A
Int J Cardiol; 2007 May; 118(2):164-9. PubMed ID: 17027104
[TBL] [Abstract][Full Text] [Related]
34. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans.
Cadroy Y; Bossavy JP; Thalamas C; Sagnard L; Sakariassen K; Boneu B
Circulation; 2000 Jun; 101(24):2823-8. PubMed ID: 10859288
[TBL] [Abstract][Full Text] [Related]
35. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity.
Valles J; Santos MT; Aznar J; Osa A; Lago A; Cosin J; Sanchez E; Broekman MJ; Marcus AJ
Circulation; 1998 Feb; 97(4):350-5. PubMed ID: 9468208
[TBL] [Abstract][Full Text] [Related]
36. [Antithrombotic agents].
Verheugt FW
Ned Tijdschr Geneeskd; 1989 Mar; 133(10):522. PubMed ID: 2710236
[No Abstract] [Full Text] [Related]
37. Nitric oxide-releasing aspirin derivative, NCX 4016, promotes reparative angiogenesis and prevents apoptosis and oxidative stress in a mouse model of peripheral ischemia.
Emanueli C; Van Linthout S; Salis MB; Monopoli A; Del Soldato P; Ongini E; Madeddu P
Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2082-7. PubMed ID: 15345513
[TBL] [Abstract][Full Text] [Related]
38. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications.
Kodela R; Chattopadhyay M; Velázquez-Martínez CA; Kashfi K
Biochem Pharmacol; 2015 Dec; 98(4):564-72. PubMed ID: 26394025
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and evaluation of nitric oxide releasing derivatives of 3-n-butylphthalide as antiplatelet and antithrombotic agents.
Wang X; Li Y; Zhao Q; Min Z; Zhang C; Lai Y; Ji H; Peng S; Zhang Y
Org Biomol Chem; 2011 Aug; 9(16):5670-81. PubMed ID: 21706121
[TBL] [Abstract][Full Text] [Related]
40. Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent.
Gresele P; Marzotti S; Guglielmini G; Momi S; Giannini S; Minuz P; Lucidi P; Bolli GB
Diabetes Care; 2010 Jun; 33(6):1262-8. PubMed ID: 20299485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
